U.S. Markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.10
    -0.61 (-1.33%)
     
  • Gold

    1,815.90
    +4.70 (+0.26%)
     
  • Silver

    23.45
    +0.00 (+0.02%)
     
  • EUR/USD

    1.1912
    -0.0007 (-0.0596%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3362
    -0.0021 (-0.1550%)
     
  • USD/JPY

    104.2520
    -0.1880 (-0.1800%)
     
  • BTC-USD

    17,168.33
    -810.84 (-4.51%)
     
  • CMC Crypto 200

    334.42
    -36.10 (-9.74%)
     
  • FTSE 100

    6,353.03
    -38.06 (-0.60%)
     
  • Nikkei 225

    26,537.31
    +240.45 (+0.91%)
     

Worldwide Anaphylaxis 2020 Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

·2 min read

The "Global Anaphylaxis Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

This report provides the most up-to-date information on key pipeline products in the global Anaphylaxis market.

It covers emerging therapies for Anaphylaxis in active clinical development stages including early and late-stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Anaphylaxis pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Anaphylaxis pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Anaphylaxis pipeline products by the company.

Short-term Launch Highlights:

Find out which Anaphylaxis pipeline products will be launched in the US and Ex-US till 2025.

Summary:

  • Anaphylaxis phase 3 clinical trial pipeline products

  • Anaphylaxis phase 2 clinical trial pipeline products

  • Anaphylaxis phase 1 clinical trial pipeline products

  • Anaphylaxis preclinical research pipeline products

  • Anaphylaxis discovery stage pipeline products

  • Anaphylaxis pipeline products short-term launch highlights

Key Topics Covered:

  1. Anaphylaxis Pipeline by Stages

  2. Anaphylaxis Phase 3 Clinical Trial Insights

  3. Anaphylaxis Phase 2 Clinical Trial Insights

  4. Anaphylaxis Phase 1 Clinical Trial Insights

  5. Anaphylaxis Preclinical Research Insights

  6. Anaphylaxis Discovery Stage Insights

  7. Appendix

  8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/tuck39

View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005660/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900